NetNoggin® releases the exploratory analysis “Coronavirus: A Comparison Between Different Therapeutic Areas”

FREDERICK, Md., April 8, 2020 /PRNewswire/ — An exploratory analysis, conducted by NetNoggin®, compares three drastically different at-risk populations’ reaction to the coronavirus crisis (including lexicon themes, volume of related conversations, and hot topics). The three therapeutic areas of focus in the analysis are:

  1. Alzheimer’s patients (the elderly)
  2. Cystic fibrosis patients (the immunocompromised)
  3. NAFLD patients (those with many comorbid conditions)

Findings from this analysis show lexicon varies significantly based on each therapeutic area. In addition, one population had mixed reactions about the severity of the coronavirus crisis. NetNoggin® is offering this exploratory analysis complimentary to professionals in the pharmaceutical industry. Visit https://netnoggin.net/exploratory-analysis to request the full exploratory analysis.

“We know from this analysis that patients in each therapeutic area will perceive the effects of the coronavirus crisis differently – and the nuance in these differences is extremely important so one can understand how to best support the patients and caregivers during this difficult time,” said Diana Conger, CEO of NetNoggin®. “This exploratory analysis gives us a baseline for our custom research because now we understand how different therapeutic areas are talking about the coronavirus, including the emotional component and trends on social media. The next step is to monitor the reported outcomes, shared resources, and best practices for specific therapeutic areas and compare them to our baseline.”

NetNoggin® will be monitoring the coronavirus’s effect on various therapeutic areas. Custom research reports are available to help drug developers understand how the coronavirus crisis is affecting their patient population(s). Sample research questions and a sample table of contents are available in the appendix of the exploratory analysis.

Contact info@netnoggin.net for more information on coronavirus-related custom research.

About NetNoggin®
NetNoggin®, a subsidiary of Conger Consulting, LLC, is a premier market research agency that specializes in pharmaceutical marketing. NetNoggin® utilizes netnography to analyze and provide context to big data. By leveraging 30+ years of experience, their proprietary process derives strategic consulting insights from big data to inform Foundational Marketing Tools (FMTs), strategies, and tactics. NetNoggin® has expertise in market research; commercial, market, and clinical development; and communications to provide reliable research, presentations, and workshops.

NetNoggin® Media Relations
If you would like more information on this topic, please contact Megan Newcomer.
E-mail: megan.newcomer@netnoggin.net

View original content to download multimedia:http://www.prnewswire.com/news-releases/netnoggin-releases-the-exploratory-analysis-coronavirus-a-comparison-between-different-therapeutic-areas-301037671.html

SOURCE NetNoggin

Staff

Recent Posts

Christopher Barnett, Founder & CEO of ABA Centers, Named Entrepreneur Of The Year 2024 Florida Winner by EY

FORT LAUDERDALE, Fla., June 17, 2024 /PRNewswire/ -- This weekend, Ernst & Young LLP (EY US)…

2 hours ago

Healthee Unveils AI-Driven Enhanced Plan Comparison Tool, Setting a New Standard in Innovative Technology for Streamlining Open Enrollment

Improved tool maximizes decision support for employees, simplifying the annual open enrollment process for organizations.…

2 hours ago

Anju Showcases Advanced eClinical Suite at DIA Global Annual Meeting 2024

FORT LAUDERDALE, Fla., June 17, 2024 /PRNewswire/ -- Anju Software, a trailblazer in comprehensive data…

2 hours ago

EHEALTH TECHNOLOGIES PARTNERS WITH CANCERX AND WHITE HOUSE CANCER MOONSHOT

PITTSBURGH, June 17, 2024 /PRNewswire/ -- eHealth Technologies -- a leading healthcare technology company that…

2 hours ago

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial Results

Revenues increased 14% in Q4 2024 compared to Q4 2023Gross profit margin improved 3% in…

2 hours ago